fig5
![Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel](https://image.oaes.cc/c45c672e-90ea-45df-8a5d-28b4693e0124/cdr60136.fig.5.jpg)
Figure 5. Effect of the docetaxel ritonavir combination in the docetaxel-resistant 22Rv1DOC8 cell line in the 3D clonogenic assay. (A) Concentration-effect curve showing a decrease of the docetaxel IC50 from 219 to 26 nM in the presence of 32 μM ritonavir; (B) Bliss Modeled T/C analysis shows synergistic effects at 32 μM ritonavir when combined with medium concentrations of docetaxel (3.16 and 10 nM).